Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for ...

Novo Nordisk has entered into an exclusive license agreement with Lexicon Pharmaceuticals Inc. for LX9851, a first-in-class, ...

Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential ...

Investing.com -- Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX) shares surged 30% following the announcement of an exclusive license agreement with Novo Nordisk (NYSE: NVO) for its developmental drug ...

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone paymentsTHE WOODLANDS, Texas, ...

As companies continually search for next-generation obesity prospects, one of the leaders in the disease space, Novo Nordisk A/S, has obtained an exclusive license to a preclinical-stage, ...

Biocatalysis is the chemical process through which enzymes or other biological catalysts perform reactions between organic components. Biocatalysis has been used widely in the pharmaceutical ...

A new study suggests early detection improves outcomes, but metabolic episodes in the first days of life still prove challenging.

Cheyenne chats with co-parents Cory Wharton and Taylor Selfridge about Ryder's possible cardiac and anxiety struggles ...